HSTM
HealthStream, Inc.
HSTM has lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over HSTM overall, supported by stronger fundamentals and stronger modeled upside.
HSTM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
HSTM's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HSTM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 38x | $28.29 | — |
| Cheap | 40x | $27.80 | -1.7% |
| Current | 40x | $28.29 | — |
| Fair | 50x | $35.27 | +25% |
| Expensive | 97x | $67.62 | +139% |
Historical ranges are pointers, not guarantees.
HSTM has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HSTM Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for HSTM, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HSTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.74 | +6.3% |
| Q3 2026 | $0.70 | +2.9% |
| Q2 2026 | $0.72 | +7.5% |
| Q1 2026 | $0.67 | +6.3% |
| Q4 2025 | $0.61 | -7.6% |
| Q3 2025 | $0.68 | +4.6% |
| Q2 2025 | $0.67 | +14% |
| Q1 2025 | $0.63 | +8.6% |
| Q4 2024 | $0.66 | +32% |
HSTM earned $0.70 per share over the past year, up 2.9% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HSTM on earnings, with more consistent year-over-year improvement.
HSTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.3M | +8.9% |
| Q2 2026 | $83.7M | +13% |
| Q1 2026 | $81.2M | +11% |
| Q4 2025 | $79.7M | +7.4% |
| Q3 2025 | $76.5M | +4.6% |
| Q2 2025 | $74.4M | +4% |
| Q1 2025 | $73.5M | +1% |
| Q4 2024 | $74.2M | +5.2% |
HSTM's revenue has grown year over year for 23 quarters in a row: $83M last quarter, up 8.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.9% | -2 points |
| Q2 2026 | 9.9% | +2 points |
| Q1 2026 | 9.3% | +3.3 points |
| Q4 2025 | 3% | -3.3 points |
| Q3 2025 | 9.9% | +1 points |
| Q2 2025 | 7.9% | +1.8 points |
| Q1 2025 | 6% | -1.9 points |
| Q4 2024 | 6.3% | +0.3 points |
HSTM's operating margin was 7.9% last quarter, down 2 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HSTM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HSTM on profitability, with a higher operating margin.
HSTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.1M | -4.8% |
| Q2 2026 | $12.5M | +363% |
| Q1 2026 | $26.4M | +1.4% |
| Q4 2025 | $13M | +19% |
| Q3 2025 | $17.9M | -4.8% |
| Q2 2025 | $2.7M | -57% |
| Q1 2025 | $26M | +29% |
| Q4 2024 | $11M | -19% |
HSTM's free cash flow has been positive every quarter for seven years: $69M over the past year, up 20% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HSTM on cash flow, with more consistent year-over-year improvement.
HSTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +342K shares |
| 1 year | -0.5% | -155K shares |
| 3 years | -3.6% | -1.1M shares |
| 5 years | -6.4% | -2M shares |
| Available history | -8.5% | -2.8M shares |
HSTM has 30M diluted shares, down 0.5% from a year ago, with $14M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $2.6M |
| Q1 2026 | $6.7M |
| Q4 2025 | $5M |
| Q3 2025 | $6.9M |
| Q4 2024 | — |
| Q4 2023 | $7.3M |
| Q3 2023 | $1.6M |
HSTM spent $14M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HSTM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HSTM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -0.8x | Net Cash |
| Q2 2025 | -0.8x | Net Cash |
| Q1 2025 | -1.3x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
HSTM has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HSTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.3 | Neutral |
| Stochastic | 34.3 | Neutral |
HSTM's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HSTM PE vs Healthcare Sector
| Metric | HSTM | Sector median | Relative |
|---|---|---|---|
| PE | 40x | 26x | 56% above |
| PE % | 19 | 29 | 10 pts below |
HSTM has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HSTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 10% below |
| 20 week MA | $29.8 | 5% below |
| 50 week MA | $25.4 | 11% above |
| 100 week MA | $27.3 | 3.7% above |
| 200 week MA | $26.7 | 5.9% above |
HSTM has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 5.9% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HSTM on trend strength, trading above more of its moving averages.
HSTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.6 | $21.7 | -21% |
| 2021 | $21.7 | $26.1 | +20% |
| 2022 | $26.1 | $24.6 | -5.9% |
| 2023 | $24.6 | $27.0 | +9.9% |
| 2024 | $27.0 | $31.8 | +17% |
| 2025 | $31.8 | $23.6 | -26% |
| 2026 YTD | $23.6 | $28.3 | +20% |
HSTM has finished lower in three of the last six years. It's up 20% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HSTM on returns for 2026, with the stronger performance.